JPMorgan analyst Anupam Rama added Neurocrine Biosciences to the firm’s Analyst Focus List, seeing 20% share upside on Ingrezza alone and "plenty of pipeline optionality" over the 12-18 months. Based on the firm’s model, the analyst values Ingrezza alone at $110-$115 per share. This value amounts to 20% upside in Neurocrine shares from current levels. The firm does not see Neurocrine’s pipeline opportunities being reflected in the shares. It keeps an Overweight rating on the name with a $126 price target.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NBIX:
- Teva’s CP trial failure may add some risk for Neurocrine, says RBC Capital
- Neurocrine announces results of published study on tardive dyskinesia
- Neurocrine to present data on Ingrezza capsule dissolution performance
- ‘2023 Rally Was a Bull Trap,’ Says Morgan Stanley. But These Stocks Still Have Upside
- Neurocrine upgraded to Outperform at Evercore with stock 25% off highs
